Cargando…

Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims

Patient access and adherence to chronic medications is critical. In this work, we evaluate whether disruptions related to Covid-19 have affected new and existing patients’ access to pharmacological therapies without interruption. We do so by performing a retrospective analysis on a dataset of 9.4 bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Clement, Jeffrey, Jacobi, Maura, Greenwood, Brad N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016279/
https://www.ncbi.nlm.nih.gov/pubmed/33793663
http://dx.doi.org/10.1371/journal.pone.0249453
_version_ 1783673826433826816
author Clement, Jeffrey
Jacobi, Maura
Greenwood, Brad N.
author_facet Clement, Jeffrey
Jacobi, Maura
Greenwood, Brad N.
author_sort Clement, Jeffrey
collection PubMed
description Patient access and adherence to chronic medications is critical. In this work, we evaluate whether disruptions related to Covid-19 have affected new and existing patients’ access to pharmacological therapies without interruption. We do so by performing a retrospective analysis on a dataset of 9.4 billion US prescription drug claims from 252 million patients from May, 2019 through August, 2020 (about 93% of prescriptions dispensed within those months). Using fixed effect (conditional likelihood) linear models, we evaluate continuity of care, how many days of supply patients received, and the likelihood of discontinuing therapy for drugs from classes with significant population health impacts. Findings indicate that more prescriptions were filled in March 2020 than in any prior month, followed by a significant drop in monthly dispensing. Compared to the pre-Covid era, a patient’s likelihood of discontinuing some medications increased after the spread of Covid: norgestrel-ethinyl estradiol (hormonal contraceptive) discontinuation increased 0.62% (95% CI: 0.59% to 0.65%, p<0.001); dexmethylphenidate HCL (ADHD stimulant treatment) discontinuation increased 2.84% (95% CI: 2.79% to 2.89%, p<0.001); escitalopram oxalate (SSRI antidepressant) discontinuation increased 0.57% (95% CI: 0.561% to 0.578%, p<0.001); and haloperidol (antipsychotic) discontinuation increased 1.49% (95% CI: 1.41% to 1.57%, p<0.001). In contrast, the likelihood of discontinuing tacrolimus (immunosuppressant) decreased 0.15% (95% CI: 0.12% to 0.19%, p<0.001). The likelihood of discontinuing buprenorphine/naloxone (opioid addiction therapy) decreased 0.59% (95% CI: 0.55% to 0.62% decrease, p<0.001). We also observe a notable decline in new patients accessing these latter two therapies. Most US patients were able to access chronic medications during the early months of Covid-19, but still were more likely to discontinue their therapies than in previous months. Further, fewer than normal new patients started taking medications that may be vital to their care. Providers would do well to inquire about adherence and provide prompt, nonjudgmental, re-initiation of medications. From a policy perspective, opioid management programs seem to demonstrate a robust ability to manage existing patients in spite of disruption.
format Online
Article
Text
id pubmed-8016279
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-80162792021-04-08 Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims Clement, Jeffrey Jacobi, Maura Greenwood, Brad N. PLoS One Research Article Patient access and adherence to chronic medications is critical. In this work, we evaluate whether disruptions related to Covid-19 have affected new and existing patients’ access to pharmacological therapies without interruption. We do so by performing a retrospective analysis on a dataset of 9.4 billion US prescription drug claims from 252 million patients from May, 2019 through August, 2020 (about 93% of prescriptions dispensed within those months). Using fixed effect (conditional likelihood) linear models, we evaluate continuity of care, how many days of supply patients received, and the likelihood of discontinuing therapy for drugs from classes with significant population health impacts. Findings indicate that more prescriptions were filled in March 2020 than in any prior month, followed by a significant drop in monthly dispensing. Compared to the pre-Covid era, a patient’s likelihood of discontinuing some medications increased after the spread of Covid: norgestrel-ethinyl estradiol (hormonal contraceptive) discontinuation increased 0.62% (95% CI: 0.59% to 0.65%, p<0.001); dexmethylphenidate HCL (ADHD stimulant treatment) discontinuation increased 2.84% (95% CI: 2.79% to 2.89%, p<0.001); escitalopram oxalate (SSRI antidepressant) discontinuation increased 0.57% (95% CI: 0.561% to 0.578%, p<0.001); and haloperidol (antipsychotic) discontinuation increased 1.49% (95% CI: 1.41% to 1.57%, p<0.001). In contrast, the likelihood of discontinuing tacrolimus (immunosuppressant) decreased 0.15% (95% CI: 0.12% to 0.19%, p<0.001). The likelihood of discontinuing buprenorphine/naloxone (opioid addiction therapy) decreased 0.59% (95% CI: 0.55% to 0.62% decrease, p<0.001). We also observe a notable decline in new patients accessing these latter two therapies. Most US patients were able to access chronic medications during the early months of Covid-19, but still were more likely to discontinue their therapies than in previous months. Further, fewer than normal new patients started taking medications that may be vital to their care. Providers would do well to inquire about adherence and provide prompt, nonjudgmental, re-initiation of medications. From a policy perspective, opioid management programs seem to demonstrate a robust ability to manage existing patients in spite of disruption. Public Library of Science 2021-04-01 /pmc/articles/PMC8016279/ /pubmed/33793663 http://dx.doi.org/10.1371/journal.pone.0249453 Text en © 2021 Clement et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Clement, Jeffrey
Jacobi, Maura
Greenwood, Brad N.
Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims
title Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims
title_full Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims
title_fullStr Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims
title_full_unstemmed Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims
title_short Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims
title_sort patient access to chronic medications during the covid-19 pandemic: evidence from a comprehensive dataset of us insurance claims
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016279/
https://www.ncbi.nlm.nih.gov/pubmed/33793663
http://dx.doi.org/10.1371/journal.pone.0249453
work_keys_str_mv AT clementjeffrey patientaccesstochronicmedicationsduringthecovid19pandemicevidencefromacomprehensivedatasetofusinsuranceclaims
AT jacobimaura patientaccesstochronicmedicationsduringthecovid19pandemicevidencefromacomprehensivedatasetofusinsuranceclaims
AT greenwoodbradn patientaccesstochronicmedicationsduringthecovid19pandemicevidencefromacomprehensivedatasetofusinsuranceclaims